Business Information
The group's principal activity is to discover and develop therapeutic drug regulatory pathways that control repair and regeneration of human tissues and organs. The group's product development involves using proteins or small molecules to modulate these pathways, so as to increase the pathway signals when they are insufficient or decrease them when they are excessive. The group has used this technology and product development strategy to produce several drug product candidates in the fields of kidney disease, neurological disorders, cancer, cardiovascular disease and hair growth regulation.
|
|
Name |
Title
|
Email
|
| James McNab | Chmn. | N/A | | Michael Gray | CFO, COO | N/A | | Changgeng Qian | VP - Discovery, Preclinical Development | N/A | | Mark Noel | VP - Technology Management, Business Development | N/A | | Daniel Passeri | Dir., CEO, Pres. | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 16,663 | (8,829) | | 2005 | 6,002 | (14,855) | | 2004 | 4,953 | (13,904)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
